# IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
Canonical URL: https://biopharmsignal.com/news/ICCM/icecure-regains-compliance-with-nasdaq-minimum-bid-price-requirement
Ticker: ICCM
Company: IceCure Medical
Source: IceCure Medical
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.icecure-medical.com
## Summary

CAESAREA, Israel, June 25, 2026 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the…...

## Article Body
, /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that on June 18, 2026, it received written notice from Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

The Nasdaq staff made this determination of compliance after the closing bid price of the Company's ordinary shares was $1.00 per share or greater for the 10 consecutive business days from June 4 to June 17, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and Nasdaq considers the bid price deficiency matter now closed.

About IceCure Medical

IceCure Medical (NASDAQ: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia.

IR Contact:

Email: investors@icecure-medical.com Meir Peleg, CFO Phone: +1-888-902-5716

Logo: https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/icecure-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302810665.html

SOURCE IceCure Medical

Released June 25, 2026
## Recent Company News
- 2026-07-14 12:32 EST — [IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation](https://biopharmsignal.com/news/ICCM/icecure-expands-u-s-commercial-team-to-meet-surging-demand-for-prosense-cryoabla-7980c317) — Source: IceCure Medical
- 2026-07-06 12:11 EST — [IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer](https://biopharmsignal.com/news/ICCM/icecure-highlights-expanding-commercial-adoption-of-prosense-cryoablation-in-bra-814ddba1) — Source: IceCure Medical
- 2026-06-25 13:46 EST — [IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement](https://biopharmsignal.com/news/ICCM/icecure-regains-compliance-with-nasdaq-minimum-bid-price-requirement) — Source: IceCure Medical
- 2026-06-25 13:46 EST — [IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer](https://biopharmsignal.com/news/ICCM/icecure-highlights-new-peer-reviewed-journal-article-in-leading-surgery-journal-demonstrating-cryoablation-s-advantages-over-radiofrequency-ablation-for-early-stage-breast-cancer) — Source: IceCure Medical
- 2026-06-25 13:46 EST — [IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor](https://biopharmsignal.com/news/ICCM/icecure-announces-pricing-of-5-5-million-private-placement-priced-at-a-premium-to-the-market-price-with-a-single-healthcare-focused-institutional-investor) — Source: IceCure Medical
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)